Joseph Dukes

Uncover how the field is moving beyond familiar targets like MAGE-A4 and PRAME to identify novel antigens that expand patient reach and improve clinical outcomes. This workshop dives into cutting-edge technologies, non-canonical targets, and next-generation engineering strategies that are redefining TCR therapy. Gain practical insights into building robust discovery pipelines, validating tumor specificity, and designing therapies that stand out in a competitive landscape.

Join this workshop to: 

• Explore emerging target spaces including non-canonical antigens, alternative HLA molecules, and strategies to increase prevalence and density for broader patient access
• Find new ways to expedite the target validation process using a broad range of tools
• Apply computational tools to discover and validate targets faster and more accurately
• Design next-generation TCR formats to maximize efficacy and durability of response